Experimental therapies for sepsis directed against tumour necrosis factor

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue SUPPL. A, 1998, Pages 65-69

  Read, Robert C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CB 0006; CYTOKINE; IMMUNOMODULATING AGENT; MAK 195F; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CLINICAL RESEARCH; COMPETITIVE INHIBITION; CONFERENCE PAPER; DISEASE SEVERITY; DRUG SAFETY; DRUG SOLUBILITY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; IN VIVO STUDY; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PATIENT; SEPSIS;

EID: 0031976120     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.suppl_1.65     Document Type: Conference Paper

References (36)

1. Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhang, A., O'Dwyer, S., Dinarello, C. A. et al. (1988). Detection of circulating tumor necrosis factor after endotoxin administration. New England Journal of Medicine 318, 1481-6.
2. Selby, P., Hobbs, S., Viner, C., Jackson, E., Jones, A., Newell, D. et al. (1987). Tumour necrosis factor in man: clinical and biological observations. British Journal of Cancer 56, 803-8.
3. van der Poll, T., Buller, H. R., ten Cate, H., Wortel, C. H., Bauer, K. A., van Deventer, S. J. et al. (1990). Activation of coagulation after administration of tumor necrosis factor to normal subjects. New England Journal of Medicine 322, 1622-7.
4. Cohen, J. & Glauser, M. P. (1991). Septic shock: treatment. Lancet 338, 736-9.
5. Calandra, T., Baumgartner, J.-D., Gran, G. E., Wu, M. M., Lambert, P. H., Schellekens, J. et al. (1990). Prognostic values of tumor necrosis factor, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Journal of Infectious Diseases 161, 982-7.
6. Marano, M. A., Fong, Y., Moldawer, L. L., Wei, H., Calvano, S. E., Tracey, K. J. et al. (1990). Serum cachectin/tumour necrosis factor in critically ill patients with burns correlates with infection and mortality. Surgery, Gynecology and Obstetrics 170, 32-8.
7. McGuire, W., Hill, V., Allsopp, E., Greenwood, B. & Kwiatowski, D. (1994). Variation in the TNF-α region associated with susceptibility to cerebral malaria. Nature 371, 508-11.
8. Stuber, F., Peterson, M., Bokelmann, F. & Schade, U. (1996). A genomic polymorphism within the tumor necrosis factor locus influences tumor necrosis factor alpha concentrations and outcome of patients with severe sepsis. Critical Care Medicine 24, 381-4.
9. Offner, F., Philippe, J., Vogelaers, D., Colardyn, F., Baele, G., Baudrihaye, M. et al. (1990). Serum tumor necrosis factor levels in patients with infectious disease and septic shock. Journal of Laboratory and Clinical Medicine 116, 100-5.
10. Seckinger, P., Isaaz, S. & Dayer, J. M. (1988). A human inhibitor of tumor necrosis factor alpha. Journal of Experimental Medicine 167, 1511-6.
11. Mohler, K. M., Torrance, D. S., Smith, C. A., Goodwin, R. G., Stremler, K. E., Fung, V. P. et al. (1993). Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. Journal of Immunology 151, 1548-61.
12. Van Zee, K. J., Kohno, T., Fischer, E., Rock, C. S., Modawer, L. L. & Lowry, S. F. (1992). Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vitro. Proceedings of the National Academy of Science of the United States of America 89, 4845-9.
13. Fiedler, V. B., Loof, I., Sander, E., Voehringer, V., Galanos, C. & Fournel, M. A. (1992). Monoclonal antibody to tumor necrosis factor-a prevents lethal endotoxin sepsis in adult rhesus monkeys. Journal of Laboratory and Clinical Medicine 120, 574-88.
14. Tracey, K. J., Fong, Y., Hesse, D. G., Manogue, K. R., Lee, A. T., Kuo, G. C. et al. (1987). Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662-4.
15. Jesmok, G., Lindsey, C., Duerr, M., Fournel, M. & Emerson, T. (1992). Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli-challenged swine. American Journal of Pathology 141,1197-207.
16. Opal, S. M., Cross, A. S., Kelly, N. M., Sadolf, J. C., Bodmer, M. W., Palardy, J. E. et al. (1990). Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. Journal of Infectious Diseases 161, 1148-52.
17. Hinshaw, L. B., Emerson, T. E., Taylor, F. B., Chang, A. C., Duerr, M., Peer, G. T. et al. (1992). Lethal Staphylococcus aureus shock in primates: prevention of death with anti-TNF antibody. Journal of Trauma 33, 568-73.
18. Exley, A. R., Cohen, J., Buurman, W., Owen, R., Hanson, G., Lumley, J. et al. (1990). Monoclonal antibody to TNF in severe septic shock. Lancet 335, 1275-7.
19. Pauli, U., Bertoni, G., Duerr, M. & Peterhans, E. (1994). A bioassay for the detection of tumor necrosis factor from eight different species: evaluation of neutralization rates of a monoclonal antibody against human TNF-a. Journal of lmmunological Methods 171, 263-5.
20. Saravolatz, L. D., Wherry, J. C., Spooner, C., Markowitz, N., Allred, R., Remick, D. et al. (1994). Clinical safety, tolerability and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor alpha. Journal of Infectious Diseases 169, 214-7.
21. Abraham, E., Wunderink, R., Silverman, H., Perl, T. M., Nasraway, S., Levy, H. et al. (1995). Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. Journal of the American Medical Association 273, 934-41.
22. Cohen, J. & Carlet, J. (1996). INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis. Critical Care Medicine 24, 1431-40.
23. Reinhart, K., Wiegard-Löhnert, C., Grimminger, F., Karl, M., Withington, S. & the MAK 195 Study Group. (1996). Assessment of the safety and efficacy of the monoclonal anti-tumour necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, doseranging study. Critical Care Medicine 24, 733-42.
24. Fekade, D., Knox, K., Jussein, K., Melka, A., Lalloo, D. G., Coxon, R. E. & Warrell, D. A. (1996). Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumour necrosis factor-α. New England Journal of Medicine 335, 31-5.
25. Evans, T. J., Moyes, D., Carpenter, A., Martin, R., Looetscher, H., Lesslauer, W. et al. (1994). Protective effect of 55-but not 75-kd soluble tumour necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of Gram-negative sepsis. Journal of Experimental Medicine 180, 2173-9.
26. Fisher, C. J., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C. et al. (1996). Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. New England Journal of Medicine 334, 1697-702.
27. Baumgartner, S., Moreland, L. W., Schiff, M. H., Tindall, E., Fleischman, R. M., Weaver, A. et al. (1996). Double-blind placebo controlled trial of tumor necrosis factor receptor (p80) fusion protein (TNFR-FC) in active rheumatoid arthritis. Arthritis and Rheumatism 39, S283.
28. The Ro45-208 Study Group. (1996). Abstracts 56, 102, 103. Intensive Care Medicine 22, Suppl. 3.
29. Dinarello, C. A. (1991). The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. Journal of Infectious Diseases 163, 1177-84.
30. Waage, A. & Espervik, T. (1988). lnterleukin 1 potentiates the lethal effect of tumor necrosis factor/alpha/cachectin in mice. Journal of Experimental Medicine 167, 1987-92.
31. Ohlsson, K., Bjork, P., Bergenfeldt, M., Hageman, R. & Thompson, R. C. (1990). lnterleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348, 550-2.
32. Fischer, E., Marano, M. A., Van Zee, K. J., Rock, C. S., Maure, A. S., Thompson, W. A. et al. (1992). lnterleukin-1 receptor blockade improves survival in hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. Journal of Clinical Investigation 89, 1551-7.
33. Russell, D. A., Tucker, K. K., Chinookoswong, N., Thompson, R. C. & Kohno, T. (1995). Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxaemia: improved survival and organ function. Journal of Infectious Diseases 171, 1528-38.
34. Opal, S. M., Cross, A. S., Jhung, J. W., Young, L. D. E., Palardy, J. E., Parejo, N. A. et al. (1996). Potential hazards of combination immunotherapy in the treatment of experimental septic shock. Journal of Infectious Diseases 173, 1415-21.
35. Bone, R. C. (1996). Why sepsis trials fail. Journal of the American Medical Association 276, 565-6.
36. Sprung, C. L., Finch, R. G., Thijs, L. G. & Glauser, M. P. (1996). International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Critical Care Medicine 24, 1441-7.